Clinical workflows in oncology rely on predictive and prognostic molecular biomarkers.
However, the growing number of these complex biomarkers tends to increase the cost and …

Background The role of tumor mutational burden (TMB) is still debated for selecting
advanced non-oncogene addicted non-small-cell lung cancer (NSCLC) patients who might …

As lung cancer remains the leading cause of cancer deaths globally, characterizing the
tumor molecular profiles is crucial to tailoring treatments for individuals at advanced stages …

Background Although immune checkpoint inhibitors (ICIs) against programmed cell death
protein 1 (PD‐1) and its ligand PD‐L1 have demonstrated potency towards treating patients …

Current lung cancer diagnosis methods encounter delayed visual confirmation of tumor foci
and low-resolution metrics in imaging findings, which delays the early treatment of tumors …

Lung cancer is the major cause of cancer death worldwide. Cancer immunotherapy has
been introduced as a promising and effective treatment that can improve the immune …

The recent development of high-throughput genomics has revolutionized personalized
medicine by identifying key pathways and molecular targets controlling tumor progression …

The relationship between circular RNA (circRNA) and cancer stem cells (CSCs) is uncertain.
We have investigated the combined influence of CSCs, circRNA (hsa_circ_0003222), and …

Acute kidney injury is a common complication of many medical procedures, including those
used in cancer treatment. Both chemotherapy and immunotherapy may result in …

MicroRNAs (miRNAs) are a type of small non-coding RNAs that play an essential role in
numerous biological processes by regulating the post-transcriptional expression of target …